CompletedNCT01066403

Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

Medication studyAges 18–65Germany

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Mannheim and 3 more locationsSee all locations and recruitment

Study clarity

Study start dateOctober 2003

Recruitment status: Completed
Enrollment listed in the registry: 28
Sponsor: Heidelberg University
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Germany
Age range: From 18 Years to 65 Years
Official registry ID: NCT01066403
Official title: Show the full official title
Dopaminergic Modulation of Prefrontal Functions in Schizophrenic Patients: Adjuvant Therapy With Pergolide

Completed

Mannheim · Heidelberg · Hamburg

1 more locations

FAQ

Who is behind this study?

The study sponsor is Heidelberg University, a university.

Did this study involve medication?

Yes. The study involved medication, including Pergolide.

Who was this study for?

Listed age limits: 18 years to 65 years.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.